In short
A new clinical trial is underway to assess the safety and effectiveness of A24110He, a promising drug for patients with type 2 diabetes and elevated triglyceride levels. This phase 2 study aims to evaluate the drug's safety, local tolerability, and pharmacodynamic profile through multiple doses in a controlled setting. The trial's findings could potentially lead to improved treatment options for individuals struggling with these conditions.
At a glance
- Study Type
- Phase 2, randomized, double-blind, placebo-controlled trial
- Drug
- A24110He (antisense oligonucleotide)
- Target Condition
- Type 2 diabetes with elevated triglycerides
- Administration
- Four weekly subcutaneous injections
- Primary Objectives
- Safety and local tolerability evaluation
- Secondary Objectives
- Exposure and pharmacodynamic profile assessment
- Key Inclusion Criteria
- Age 18-75, history of hypertriglyceridemia, fasting triglycerides ≥ 2.5 mmol/L, stable type 2 diabetes treatment
- Key Exclusion Criteria
- Recent cardiovascular events, uncontrolled hypertension, HbA1c >70 mmol/mol, active malignancy
- Primary Endpoints
- Physical examination, local tolerability, vital signs, safety lab tests, adverse events
- Secondary Endpoints
- Plasma concentrations of A24110He, pharmacokinetic parameters, fasting triglyceride levels
What is A24110He?
A24110He is a new investigational drug being studied for its potential to help people with type 2 diabetes who also have high levels of triglycerides in their blood. It belongs to a class of drugs called antisense oligonucleotides (ASOs), which are designed to target specific genetic instructions in the body.
Medical Conditions Treated
The main condition that A24110He aims to treat is called moderate to severe hypertriglyceridemia. This is a medical term that means having high levels of triglycerides (a type of fat) in the blood. Specifically, the drug is being tested in people who have:
- Type 2 diabetes: A condition where the body doesn't use insulin properly, leading to high blood sugar levels
- Elevated triglycerides: Fasting triglyceride levels of 2.5 mmol/L or higher
How A24110He Works
While the exact mechanism isn't fully described in the trial information, A24110He is an antisense oligonucleotide (ASO). ASOs work by interfering with the genetic instructions that lead to the production of certain proteins in the body. In this case, A24110He likely targets genes involved in triglyceride production or metabolism, aiming to lower triglyceride levels in the blood.
Clinical Trial Details
A24110He is currently being studied in a Phase 2 clinical trial. Here are some key details about the study:
- It's a randomized, double-blind, placebo-controlled trial. This means that participants are randomly assigned to receive either A24110He or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study.
- The drug is given as a subcutaneous injection (an injection under the skin).
- Participants receive four weekly administrations of the drug.
- The main goal is to evaluate the safety and local tolerability of A24110He.
- Secondary goals include studying how the drug is processed by the body (pharmacokinetics) and how it affects triglyceride levels (pharmacodynamics).
Eligibility Criteria
The study has specific criteria for who can participate. Some key eligibility factors include:
- Age 18-75 years
- Body Mass Index (BMI) less than 38 kg/m² and body weight of at least 56 kg
- History of hypertriglyceridemia (high triglycerides)
- Fasting triglyceride levels of 2.5 mmol/L or higher
- For those with type 2 diabetes, stable glucose-lowering treatment for at least 3 months
There are also several exclusion criteria, such as recent major health events, certain medications, and other health conditions that might interfere with the study results.
Safety and Monitoring
The trial includes extensive safety monitoring to protect participants' health. This includes:
- Physical examinations
- Vital signs monitoring: Including blood pressure, heart rate, and body temperature
- Blood tests: To check liver function, kidney function, blood sugar levels, and other important health indicators
- Urine tests
- Monitoring for side effects: The frequency, seriousness, and intensity of any adverse events will be closely tracked
Potential Benefits
While it's important to note that A24110He is still in the testing phase and its benefits are not yet proven, the potential advantages being studied include:
- Lowering of triglyceride levels in the blood
- Possible improvement in overall metabolic health for people with type 2 diabetes and high triglycerides
It's crucial to remember that more research is needed to fully understand the effects and potential benefits of A24110He. The ongoing clinical trial will provide important information about its safety and effectiveness.